Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure (PH-HF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01545180
Recruitment Status : Recruiting
First Posted : March 6, 2012
Last Update Posted : November 24, 2017
CHRU Lille, Dr Nicolas LAMBLIN
Information provided by (Responsible Party):
Thibaud Damy, French Cardiology Society

February 29, 2012
March 6, 2012
November 24, 2017
February 2012
July 2018   (Final data collection date for primary outcome measure)
Prognostic [ Time Frame: 2 years ]
Estimate the prognosis of different forms of HTPcap in heart failure (ejection fraction altered, stored or valvular heart disease)
Same as current
Complete list of historical versions of study NCT01545180 on Archive Site
  • Prevalence [ Time Frame: 3 years ]
    Define the prevalence of different forms of active or passive HTPcap
  • Phenotype [ Time Frame: 3 years ]
    Define the phenotypic characteristics of patients with reactive or passive HTPcap in heart failure
Same as current
Not Provided
Not Provided
Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure
Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure.
This study will better understand the post-capillary pulmonary hypertension in heart failure, to determine its prognostic role and to consider specific treatment of different forms of pulmonary hypertension in post-capillary pulmonary heart failure.

Patients with heart failure (HF) frequently have a post-capillary pulmonary hypertension (HTPcap) which has two forms: passive and reactive.

The prognosis, prevalence and pathophysiological mechanisms of cell and tissue involved in the onset and reversibility of these two forms of HTPcap remain poorly understood.

The latest recommendations of the European Society of Cardiology and the European Respiratory Society identify two forms of HTPcap in the IC as a function of the extent of trans-pulmonary gradient (GTP) measured during right heart catheterization (GTP = mPAP-Pcap): passive (GTP £ 12mmHg) and reactive (GTP> 12mmHg).

In the latter form, the increase in pulmonary pressure would be disproportionate to the increase in left ventricular pressures.

This study will permit to identify hemodynamic prognostic markers of the the IC, and clinical, biological and hemodynamic determinants of the HTPcap in the IC.

This will help to identify a population that could benefit from specific treatment to referred pulmonary artery.

Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
  • 3 tubes of 6 blood for analysis of biomarkers
  • 2 tubes of 6 mL blood for DNA analysis
Non-Probability Sample
Inclusion of consecutive patients recruted from cardiology departments for all participating centres. Participation in the study is offered to all French institutions (academic hospitals, general hospitals, army hospitals and private clinics) with cardiology units. A physician is responsible for study recruitment at each centre.
  • Heart Failure
  • Post-capillary Pulmonary Hypertension
Not Provided
HTPcap in IC
HTPcap active and passive in a population of stable patients with heart failure (left ventricular ejection fraction impaired or preserved) and / or valvular disease who received a left right heart catheterization as part of their care.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
December 2018
July 2018   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient with heart failure (LVEF preserved or altered or valvular heart disease) defined by a history of heart failure or LVEF less than or equal to 50%.
  • Patient with a right heart catheterization for medical reasons
  • Medical treatment considered optimal: beta blockers, ACE inhibitors or angiotensin II receptor antagonists and/or aldosterone
  • Stable Patient: No significant cardiac decompensation or change the dose of diuretics for 28 days.
  • The patient has agreed and have signed consent.

Exclusion Criteria:

  • Patient is younger than 18 years.
  • Patient with unstable heart failure (cardiogenic shock, acute cardiac decompensation).
  • Coronary heart disease for which there is a maximum revascularization
  • Organic valvular which is scheduled for surgical correction of valvular abnormality (plasty or replacement).
  • Patient dialysis.
  • PAH original pre-capillary catheterization, defined by a Pcap ≤ 15 mmHg.
  • Patient with triple installation of PM within 90 days.
  • Patients who underwent revascularization within 90 days.
  • Patients who underwent mechanical ventricular assistance.
  • Patient with severe lung infection (CPT < 60% of predicted, FEV < 60% predicted) or pulmonary embolism or respiratory failure with a paO2 in ambient air below 60mmHg or oxygen therapy.
  • Patient with severe heart rhythm.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact: Tibaud DAMY 33(0)144907028
Contact: Genevieve Mulak 33(0)143223333
Not Provided
Not Provided
Thibaud Damy, French Cardiology Society
French Cardiology Society
CHRU Lille, Dr Nicolas LAMBLIN
Principal Investigator: Thibaud DAMY Assistance Publique - Hôpitaux de Paris
French Cardiology Society
November 2017